MeAgain simplifies the complex processes of protein, hydration, movement, and shot tracking into a simple, measurable routine
For example, chronic low-grade inflammation, or "inflammaging," exacerbates tissue damage and is modulated by NAD+-dependent enzymes
The IR of all-cause mortality was 9.5 in GLP-1RA users and 16.9 in non-users
The patient should generally have at least 1216 weeks of treatment, and preferably longer if dose escalation has been slow
The peptides compact structure and D-amino acid content contribute to resistance to enzymatic degradation
Why Retatrutide Is Mechanistically Distinct Retatrutide is the first triple receptor agonist in human clinical trials in the GLP-1 class